5:26 am KaloBios Pharma comments on acquisition of shares by group comprised of Martin Shkreli and associates, says in discussions with the group regarding possible direction for the company to continue in operation (KBIO) :
The co announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding possible direction for the company to continue in operation. Mr. Shkreli is the founder and chief executive officer of Turing Pharmaceuticals
Shkreli became a poster boy of sorts for high-priced pharmaceuticals when The New York Times wrote about Turing earlier this year, noting the company had bought an infectious-disease drug that previously sold for $13.50 a pill and increased that price to $750. Shkreli said after an uproar that he would cut the price of the drug.
KBIO closed at $2.07 yesterday, indicated at $16.07 premarket
No comments:
Post a Comment